Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Pharmaocogenomic Characterization of MCL-1 Inhibitor Response and Resistance in Aggressive B-Cell Lymphomas

Michelle Wang, BSE, Tao Li, MD, Yuan Ren, PhD, Bijal Shah, MD, Tint Lwin, MD PhD, Jing Gao, PhD, Kenneth H. Shain, MD PhD, Wei Zhang, PhD, Xiaohong Zhao, MD PhD, Jianguo Tao, MD PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-141407

Published: 2020

Journal Articles

CDK9 As a New Therapeutic Vulnerability for Ibrutinib Resistance Mantle Cell Lymphoma (MCL)

Michelle Wang, BSE, Xiaohong Zhao, MD PhD, Huijuan Jiang, MD, Joy Catherine Yan, Eduardo Sotomayor, MD, Kenneth H. Shain, MD PhD, Bijal Shah, MD, Jianguo Tao, MD PhD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-141386

Published: 2020

Journal Articles

C-Myc Driven Tolerogenic Tumor Microenvironment (TME) in Mantle Cell Lymphoma (MCL) Is Overcome By Bromodomain Inhibition

Fengdong Cheng, MD, Yuan Ren, PhD, Jie Chen, PhD, Zi Wang, B.S., Tao Li, MD, Kieron Dunleavy, MD, Jianqing Lin, MD, James Bradner, MD, Mitchell R. Smith, MDPhD, Bijal D. Shah, MD, Eduardo Sotomayor, MD, Jianguo Tao, MD PhD

Blood (2018) 132 (Supplement 1): 777.

https://doi.org/10.1182/blood-2018-99-116865

Published: 2018

Journal Articles

Targeting Oncoprotein Translation with Rocaglates in MYC-Driven Lymphoma

Xuan Zhang, BMBS, Chengfeng Bi, MD PhD, Ting Lu, MD PhD, Ting Yue, Weiwei Zhang, PhD, Xiaoyan Zhang, MD, Wang Cheng, MD, Tian Tian, MD, Matthew A. Lunning, DO, Julie M. Vose, MDMBA, Jerry Pelletier, PhD, John A Porco, Jr., PhD, Jianguo Tao, MD PhD, Kai Fu, MD PhD

Blood (2018) 132 (Supplement 1): 38.

https://doi.org/10.1182/blood-2018-99-117659

Published: 2018

Journal Articles

Targeting Kinome Reprogramming for Overcoming Ibrutinib-Resistance (IR) in Mantle Cell Lymphoma (MCL)

Xiaohong Zhao, MD PhD, Huijuan Jiang, MD, Michelle Wang, Tao Li, MD, Jing Gao, PhD, Tint Lwin, MD PhD, Yuan Ren, PhD, Eduardo Sotomayor, MD, Bijal D. Shah, MD, Jianguo Tao, MD PhD

Blood (2018) 132 (Supplement 1): 2651.

https://doi.org/10.1182/blood-2018-99-116756

Published: 2018

Journal Articles

Pharmacoproteomics Identifies PLK1 As Vulnerability for Aggressive B-Cell Lymphomas

Blood (2018) 132 (Supplement 1): 2853.

https://doi.org/10.1182/blood-2018-99-118004

Published: 2018

Journal Articles

BRD4: epigenetic origin and target of CTCL

Xiaohong Zhao, Jianguo Tao

Blood (2018) 131 (7): 712–713.

https://doi.org/10.1182/blood-2017-12-820266

Published: 2018

Journal Articles

Venetoclax As a Single Agent and in Combination with PI3K-mTOR1/2 Kinase Inhibitors Against Ibrutinib Sensitive and Resistant Mantle Cell Lymphoma

Huijuan Jiang, MD, Tint Lwin, MD PhD, Bijal D. Shah, MD, Grace T Li, Yuan Ren, Michael W Yan, Lynn C. Moscinski, MD, Xiaohong Zhao, MD PhD, Jianguo Tao, MD PhD

Blood (2017) 130 (Supplement 1): 5197.

https://doi.org/10.1182/blood.V130.Suppl_1.5197.5197

Published: 2017

Journal Articles

JQ1, a Selective Bromodomain Inhibitor, Augment the Immunogenicity of Mantle Cell Lymphoma By Influencing the Expression of PD-L1

Hongwei Wang, MD, Fengdong Cheng, MD, Jie Cheng, PhD, Alejandro Villagra, PhD, Jianguo Tao, MD PhD, James E. Bradner, MD, Eduardo M. Sotomayor, MD

Blood (2015) 126 (23): 822.

https://doi.org/10.1182/blood.V126.23.822.822

Published: 2015

Journal Articles

Polycomb genes, miRNA, and their deregulation in B-cell malignancies

Gang Greg Wang, Kyle D. Konze, Jianguo Tao

Blood (2015) 125 (8): 1217–1225.

https://doi.org/10.1182/blood-2014-10-606822

Published: 2015

Journal Articles

Seven Year Followup for Bystander Vaccine Therapy in Mantle Cell Lymphoma (MCL)

Bijal D. Shah, MD, Jianguo Tao, MD PhD, Paul A. Chervenick, MD, Marcie L Riches, MD MS, Javier Pinilla-Ibarz, MD PhD, Lynn C. Moscinski, MD, Scott Antonia, MD, Eduardo M. Sotomayor, MD, Sophie Dessureault, MD

Blood (2014) 124 (21): 3083.

https://doi.org/10.1182/blood.V124.21.3083.3083

Published: 2014

Journal Articles

Increased Treatment Intensity Is Not Associated with a Survival Benefit in Patients with Low and Intermediate Risk Mantle Cell Lymphoma, a Retrospective Analysis

Patrick T. Griffin, MD, Julio C Chavez, MD, Celeste M. Bello, MD, Lubomir Sokol, MD PhD, Paul A. Chervenick, MD, Ernesto Ayala, MD, Jianguo Tao, MD PhD, Eduardo M. Sotomayor, MD, Bijal D. Shah, MD

Blood (2014) 124 (21): 4424.

https://doi.org/10.1182/blood.V124.21.4424.4424

Published: 2014

Journal Articles

JQ 1, a Selective Bromodomain Inhibitor, Decreased the Expression of the Tolerogenic Molecule PDL1 in Antigen-Presenting Cells (APCs) and Restores the Responsiveness of Anergic CD4+ T Cells

Hongwei Wang, MD, Fengdong Cheng, MD, Limin Xing, MD, Xiaohong Zhao, PhD, Alejandro Villagra, PhD, Javier Pinilla-Ibarz, MD PhD, Jianguo Tao, MD PhD

Blood (2014) 124 (21): 2749.

https://doi.org/10.1182/blood.V124.21.2749.2749

Published: 2014

Journal Articles

Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Fengdong Cheng, MD, Bing Xia, MD, Eva Sahakian, PhD, Tint Lwin, MD PhD, Hongwei Wang, MD, Limin Xing, MD, Bijal D. Shah, MD, Patricio PerezVillarroel, BS, Maritza LienlafMoreno, BS, Yizhuo Zhang, MD, Steven N Quayle, PhD, Simon S Jones, PhD, Javier Pinilla-Ibarz, MD PhD, Alejandro Villagra, PhD, Eduardo M. Sotomayor, MD, Jianguo Tao, MD PhD

Blood (2014) 124 (21): 5397.

https://doi.org/10.1182/blood.V124.21.5397.5397

Published: 2014

Journal Articles

Expression of p-STAT5, c-MYC and IKZF1 By Immunohistochemistry May Differentially Correlate with Clinical Outcome in Adult B- Lymphoblastic Leukemia (B-ALL) According to BCR-ABL Status

Bijal D. Shah, MD, Saloomeh Vahdat, MD, Jianguo Tao, MD PhD, Lynn C. Moscinski, MD, Ling Zhang, MD

Blood (2014) 124 (21): 3779.

https://doi.org/10.1182/blood.V124.21.3779.3779

Published: 2014

Journal Articles

Locally Directed Therapy In Limited Stage Mantle Cell Lymphoma

Samir Dalia, MD, Julio C Chavez, MD, Celeste M. Bello, MD, Paul A. Chervenick, MD, Lubomir Sokol, MD, Ph.D, Jianguo Tao, MD, PhD, Eduardo M. Sotomayor, MD, Bijal D. Shah, MD

Blood (2013) 122 (21): 5057.

https://doi.org/10.1182/blood.V122.21.5057.5057

Published: 2013

Journal Articles

Expression Level Of p-STAT5, c-MYC and IKZF1 By Immunohistochemistry Might Correlate With Adverse Clinic Outcome In Adult B- Lymphoblastic Leukemia (B-ALL)

Jiangchuan Tao, MD, PhD, Bijal D. Shah, MD, Xiaohui Zhang, MD, Prerna Rastogi, MBBS, PhD, Jianguo Tao, MD, PhD, Jeffrey E Lancet, MD, Michael Nieder, Hui-Yi Lin, Ph.D, Eduardo M. Sotomayor, MD, Lynn Moscinski, MD, Ling Zhang, MD

Blood (2013) 122 (21): 3875.

https://doi.org/10.1182/blood.V122.21.3875.3875

Published: 2013

Journal Articles

Whole Genome and Exome Sequencing Defines The Genetic Landscape Of Hepatosplenic T-Cell Lymphoma

Blood (2013) 122 (21): 842.

https://doi.org/10.1182/blood.V122.21.842.842

Published: 2013

Journal Articles

Combination of ACY1215, a Selective Histone Deacetylase 6 (HDAC6) Inhibitor with the Bruton Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Represents a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Eva Sahakian, Ph.D, Jennifer Rock-Klotz, B.S., Bijal D. Shah, MD, John Powers, B.S., Jennifer L. Cultrera, MD, Susan Deng, David M Woods, M.S., Michael Nguyen, Fengdong Cheng, MD, Hongwei Wang, Patricio Perez-Villarroel, B.S., Maritza Lienlaf, B.S., Tesa Knox, M.S., Selina Chen-Kiang, PhD, Alejandro Villagra, PhD, Jianguo Tao, MD, PhD, Javier Pinilla-Ibarz, MD, PhD, Simon S Jones, Eduardo M. Sotomayor, MD

Blood (2012) 120 (21): 1660.

https://doi.org/10.1182/blood.V120.21.1660.1660

Published: 2012

Journal Articles

Silencing c-Myc Using Myc Inhibitor JQ1 and EZH2 Inhibitor DZNep Blocks Converging Survival Signals in Aggressive B-Cell Lymphomas

Xiaohong Zhao, PhD, Tint Lwin, MD, PhD, Xinwei Zhang, MD, Andy Huang, Jian Wang, Victor E. Marquez, PhD, Selina Chen-Kiang, PhD, James E Bradner, MD, William S. Dalton, PhD, MD, Eduardo M. Sotomayor, MD, Jianguo Tao, MD, PhD

Blood (2012) 120 (21): 4618.

https://doi.org/10.1182/blood.V120.21.4618.4618

Published: 2012

NARROW

Pharmaocogenomic Characterization of MCL-1 Inhibitor Response and Resistance in Aggressive B-Cell Lymphomas

CDK9 As a New Therapeutic Vulnerability for Ibrutinib Resistance Mantle Cell Lymphoma (MCL)

C-Myc Driven Tolerogenic Tumor Microenvironment (TME) in Mantle Cell Lymphoma (MCL) Is Overcome By Bromodomain Inhibition

Targeting Oncoprotein Translation with Rocaglates in MYC-Driven Lymphoma

Targeting Kinome Reprogramming for Overcoming Ibrutinib-Resistance (IR) in Mantle Cell Lymphoma (MCL)

Pharmacoproteomics Identifies PLK1 As Vulnerability for Aggressive B-Cell Lymphomas

BRD4: epigenetic origin and target of CTCL

Venetoclax As a Single Agent and in Combination with PI3K-mTOR1/2 Kinase Inhibitors Against Ibrutinib Sensitive and Resistant Mantle Cell Lymphoma

JQ1, a Selective Bromodomain Inhibitor, Augment the Immunogenicity of Mantle Cell Lymphoma By Influencing the Expression of PD-L1

Polycomb genes, miRNA, and their deregulation in B-cell malignancies

Seven Year Followup for Bystander Vaccine Therapy in Mantle Cell Lymphoma (MCL)

Increased Treatment Intensity Is Not Associated with a Survival Benefit in Patients with Low and Intermediate Risk Mantle Cell Lymphoma, a Retrospective Analysis

JQ 1, a Selective Bromodomain Inhibitor, Decreased the Expression of the Tolerogenic Molecule PDL1 in Antigen-Presenting Cells (APCs) and Restores the Responsiveness of Anergic CD4+ T Cells

Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Expression of p-STAT5, c-MYC and IKZF1 By Immunohistochemistry May Differentially Correlate with Clinical Outcome in Adult B- Lymphoblastic Leukemia (B-ALL) According to BCR-ABL Status

Locally Directed Therapy In Limited Stage Mantle Cell Lymphoma

Expression Level Of p-STAT5, c-MYC and IKZF1 By Immunohistochemistry Might Correlate With Adverse Clinic Outcome In Adult B- Lymphoblastic Leukemia (B-ALL)

Whole Genome and Exome Sequencing Defines The Genetic Landscape Of Hepatosplenic T-Cell Lymphoma

Combination of ACY1215, a Selective Histone Deacetylase 6 (HDAC6) Inhibitor with the Bruton Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Represents a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Silencing c-Myc Using Myc Inhibitor JQ1 and EZH2 Inhibitor DZNep Blocks Converging Survival Signals in Aggressive B-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only